- Home
- IVP vs DRMA Comparison
IVP vs DRMA Comparison
Compare IVP & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- DRMA
- Stock Information
- Founded
- IVP 2020
- DRMA 2014
- Country
- IVP United States
- DRMA United States
- Employees
- IVP N/A
- DRMA N/A
- Industry
- IVP Diversified Commercial Services
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- DRMA Health Care
- Exchange
- IVP Nasdaq
- DRMA Nasdaq
- Market Cap
- IVP 3.4M
- DRMA 3.3M
- IPO Year
- IVP 2023
- DRMA 2021
- Fundamental
- Price
- IVP $0.99
- DRMA $4.25
- Analyst Decision
- IVP
- DRMA Strong Buy
- Analyst Count
- IVP 0
- DRMA 1
- Target Price
- IVP N/A
- DRMA $10.00
- AVG Volume (30 Days)
- IVP 166.9K
- DRMA 349.4K
- Earning Date
- IVP 11-12-2025
- DRMA 11-12-2025
- Dividend Yield
- IVP N/A
- DRMA N/A
- EPS Growth
- IVP N/A
- DRMA N/A
- EPS
- IVP N/A
- DRMA N/A
- Revenue
- IVP $15,292,904.00
- DRMA N/A
- Revenue This Year
- IVP N/A
- DRMA N/A
- Revenue Next Year
- IVP N/A
- DRMA N/A
- P/E Ratio
- IVP N/A
- DRMA N/A
- Revenue Growth
- IVP N/A
- DRMA N/A
- 52 Week Low
- IVP $0.63
- DRMA $3.83
- 52 Week High
- IVP $24.61
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- IVP 51.76
- DRMA 40.73
- Support Level
- IVP $0.93
- DRMA $3.83
- Resistance Level
- IVP $1.00
- DRMA $5.18
- Average True Range (ATR)
- IVP 0.07
- DRMA 0.44
- MACD
- IVP -0.01
- DRMA -0.10
- Stochastic Oscillator
- IVP 28.60
- DRMA 20.50
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.